Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas transaction involving its long-acting peptide drug metabolism AI discovery platform, which includes a USD 1.2 billion upfront payment, up to USD 3.5 billion in development milestones, and up to USD 13.8 billion in potential sales milestones, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is the largest among domestic pharmaceutical companies in the year and is comparable to the 2015 upfront payment scale between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a high apparent year-on-year growth in net profit for 2026 [1][3]. Summary by Sections Transaction Details - The deal with AstraZeneca includes a USD 1.2 billion upfront payment, a maximum of USD 3.5 billion in development milestones, and a maximum of USD 13.8 billion in potential sales milestones, along with a double-digit percentage royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R (monthly formulations) and three preclinical weight loss pipelines with different mechanisms of action [2]. Platform Mechanism - The company possesses a globally leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company’s pipeline includes significant projects such as EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The company is focusing on filling gaps in its wild-type lung squamous carcinoma layout with PD-1/IL-15 and has ADC pipelines targeting HER3, B7H3, DLL3, among others [3]. Profit Forecast and Valuation - The company’s net profit is projected to be RMB 4.45 billion in 2025 and RMB 8.46 billion in 2026, with corresponding EPS of RMB 0.39 and RMB 0.73 [4][9]. - The target price is set at HKD 19.25, reflecting a 24x PE for 2026, with adjustments made based on the anticipated impact of product procurement [4][11].

股票研究 /[Table_Date] 2026.02.01 持续推荐创新药械产业链 [Table_Industry] 医药 ——国泰海通医药 2026 年 2 月月报 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 郑琴(分析师) | 021-23219808 | zhengqin@gtht.com | S0880525040108 | | 谈嘉程(分析师) | 021-38038429 | tanjiacheng@gtht.com | S0880523070004 | 本报告导读： 持续推荐创新药械及产业链。 投资要点： | [Table_Invest] | | | --- | --- | | 评级： | 增持 | [Table_Report] 相关报告 医药《V940 五年随访数据披露，mRNA 肿瘤疫 苗长期价值验证》2026.01.30 医药《支持政策不断，持续推荐创新药械产业 链》202 ...

股票研究 /[Table_Date] 2026.02.01 持续推荐创新药械产业链 [Table_Industry] 医药 ——国泰海通医药 2026 年 2 月月报 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 郑琴(分析师) | 021-23219808 | zhengqin@gtht.com | S0880525040108 | | 谈嘉程(分析师) | 021-38038429 | tanjiacheng@gtht.com | S0880523070004 | 本报告导读： 持续推荐创新药械及产业链。 投资要点： | [Table_Invest] | | | --- | --- | | 评级： | 增持 | [Table_Report] 相关报告 医药《V940 五年随访数据披露，mRNA 肿瘤疫 苗长期价值验证》2026.01.30 医药《支持政策不断，持续推荐创新药械产业 链》202 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas deal for its long-acting peptide drug metabolism AI discovery platform, involving an upfront payment of USD 1.2 billion, potential R&D milestone payments of up to USD 3.5 billion, and sales milestone payments of up to USD 13.8 billion, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is noted as the largest deal in the domestic pharmaceutical sector for the year, comparable to a previous major deal between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a projected rapid year-on-year growth in net profit for 2026 [1]. - The long-acting metabolism platform is considered rare globally, with only Camurus having a similar platform, which enhances the company's competitive position in the overseas weight loss market [2]. Summary by Sections Transaction Details - The deal with AstraZeneca includes an upfront payment of USD 1.2 billion, potential R&D milestones of up to USD 3.5 billion, and sales milestones of up to USD 13.8 billion, along with a royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R and three preclinical weight loss pipelines, with plans for collaboration on four additional projects [2]. Platform Mechanism - The company possesses a leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company has a robust pipeline including EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The ADC pipeline targets HER3, B7H3, DLL3, and aims to address gaps in lung squamous carcinoma treatment [3]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are estimated at RMB 4.45 billion, RMB 8.46 billion, and RMB 5.60 billion respectively, with corresponding EPS of RMB 0.39, RMB 0.73, and RMB 0.49 [4][9]. - The company is assigned a PE ratio of 24 times for 2026, with a target price adjustment reflecting market conditions [4][11].

中国创新药出海BD再获里程碑式突破！ 1月30日，石药集团宣布已与全球生物制药领导者阿斯利康签订战略研发合作与授权协议，以利用集团 专有的缓释给药技术平台及多肽药物AI发现平台，开发创新长效多肽药物。若后续所有研发及销售里 程碑均达成，石药集团方面有权获得总计高达185亿美元的款项。 据不完全统计，本次交易刷新了中国药企BD交易总金额最高纪录，超过了此前启德医药与 Biohaven&AimedBio达成的一笔130亿美元交易。其12亿美元的预付款，仅次于此前三生制药与辉瑞就 PD-1/VEGF达成的数额。 不过，二级市场反应不佳，石药集团股价高开低走，盘中一度狂泻近13%，收跌10.2%。什么原因？分 析人士指出，或系多方面因素叠加影响。 从石药集团股价近日表现来看，市场可能提前定价。在此次协议公告前，石药集团已连续多日强势上 涨，尤其在1月28日，股价单日大涨6.14%创年内新高。公告发布后，部分资金可能选择获利了结，形 成"利好兑现"式抛压。 从业绩贡献来看，尽管协议总金额高达185亿美元，但预付款为12亿美元，其余173亿美元为研发与销售 里程碑付款，需在未来数年、多个临床阶段成功推进后方可兑现，短期现 ...

Group 1 - The event themed "ESG-driven New Productive Forces, Building a New Ecosystem for the Pudong Headquarters Economy" was held in Shanghai, focusing on sustainable development and ESG-related themes [1] - The "2025 Pudong New Area Sustainable Development (ESG) Leading Sample" and the "Pudong New Area ESG Industry Ecological Innovation Competition" were announced, with Hansoh Pharmaceutical recognized for its practices in improving diagnosis and treatment levels for Neuromyelitis Optica Spectrum Disorders (NMOSD) [1] Group 2 - NMOSD is a rare autoimmune disease affecting the central nervous system, with an incidence rate of approximately (0.5-3.4)/100,000 globally, and its treatment is complex [2] - Hansoh Pharmaceutical introduced the world's first humanized CD19 monoclonal antibody, XinYue® (Inalizumab Injection), for treating adult NMOSD patients, which was approved in China in 2022 [2] - The company has also received approval for a second rare disease indication for XinYue® in treating adult patients with Immunoglobulin G4-related disease (IgG4-RD) and has a third application for generalized Myasthenia Gravis (gMG) under review [2] Group 3 - As a leading innovative pharmaceutical company in China, Hansoh Pharmaceutical is committed to enhancing the accessibility and affordability of rare disease medications [3] - The company has increased its investment in R&D for "anti-tumor, anti-infection, central nervous system, metabolic, and autoimmune" diseases, with 7 innovative drugs included in the national medical insurance directory [3] - By the first half of 2025, sales revenue from innovative drugs and cooperative products accounted for over 82.7% of the company's total revenue, highlighting innovation as a core driver of its mission and vision [3] - Hansoh Pharmaceutical has received high recognition for its performance in corporate governance, R&D innovation, environmental protection, social responsibility, and talent development, achieving MSCI AA rating and inclusion in the S&P Global Sustainability Yearbook [3]

Core Viewpoint - The strategic collaboration between Shijiazhuang Pharmaceutical Group and AstraZeneca marks a significant milestone in the outbound business development (BD) of Chinese innovative drugs, with a potential total payment of up to $18.5 billion, setting a new record for BD transactions in the Chinese pharmaceutical industry [1][3]. Group 1: Transaction Details - Shijiazhuang Pharmaceutical has signed a strategic R&D cooperation and licensing agreement with AstraZeneca, utilizing its proprietary sustained-release drug delivery technology and peptide drug AI discovery platform to develop innovative long-acting peptide drugs [1]. - The total potential payment of $18.5 billion includes an upfront payment of $1.2 billion, with the remaining $17.3 billion contingent on achieving various R&D and sales milestones over the coming years [3]. Group 2: Market Reaction - Despite the significant deal, Shijiazhuang Pharmaceutical's stock experienced a sharp decline, dropping nearly 13% intraday and closing down 10.2%, attributed to profit-taking after a strong pre-announcement stock performance [1][3]. - The overall market sentiment was also negative, with major indices in Hong Kong, including the Hang Seng Index and the Hang Seng Biotechnology Index, falling over 2%, impacting the performance of other leading Chinese biopharmaceutical companies [3]. Group 3: Industry Outlook - Analysts suggest that the core logic of domestic innovative drugs remains solid, indicating a favorable window for investment as the BD of Chinese companies accelerates and the price gap for innovative drugs between China and the U.S. narrows, presenting significant long-term growth potential [5]. - The Hong Kong Stock Connect innovative drug ETF (520880) has seen substantial net subscriptions, indicating ongoing investor interest despite recent market volatility [4].

Core Viewpoint - China Galaxy Securities is optimistic about the pharmaceutical industry's investment opportunities in 2026, focusing on hard technology in medicine, innovation, and overseas expansion, while seeking alpha in niche segments [1] Group 1: Investment Trends - In Q4 2025, public fund holdings in pharmaceuticals decreased, indicating an overall low allocation level [1] - The market value of pharmaceutical theme funds decreased by 9.73% to 205.9 billion yuan, which is 66.54% higher than the average since 2019 [1] - The market value of the pharmaceutical biotechnology sector fell by 18.81% to 312.5 billion yuan, with a holding ratio of 8.12%, below the historical average by 3.89 percentage points [1] Group 2: Stock Performance - The top five pharmaceutical stocks held by public funds in Q4 2025 saw significant reductions in both the number of funds and total market value, with notable declines in stocks like Heng Rui Medicine and WuXi AppTec [2] - The concentration of holdings has shifted from innovative drugs to medical devices and services, indicating a change in market investment focus [2] Group 3: Industry Data Overview - The pharmaceutical manufacturing industry's revenue has shown a slight decline, with a year-on-year decrease of 1.2% in Q4 2025 [3] - Medical service volumes remained stable, with a total of 1.86 billion outpatient visits in early 2025, reflecting a 0.1% year-on-year decrease [3] - The overall operation of the medical insurance fund has been stable, with total income of 2.632 trillion yuan and total expenditure of 2.110 trillion yuan from January to November 2025 [3] Group 4: Market Comparison - The pharmaceutical industry has underperformed compared to the CSI 300 index, with a rolling P/E ratio of 38.19 compared to 14.14 for the CSI 300, indicating a premium of 170.14% over the index [3] - The SW pharmaceutical biotechnology index increased by 1.44% from early 2024 to January 28, 2026, while the CSI 300 rose by 37.15%, showing a relative underperformance of 35.71% for the pharmaceutical sector [3]

有望凭借高可及性、优异的疗效成为不逊于pluvicto（50亿美元销售峰值预期）的前列腺癌重磅药物。 （映恩生物） B7-H3 ADC 爆发前夜：III 期密集落地，千亿市场雏形初现 事件：2026年1月26日，clinicaltrials网址显示，BioNTech启动了BNT324（DB-1311）的首个III期临床试验（化疗未 经治的转移性去势抵抗性前列腺癌mCRPC，DB-1311vs多西他赛+泼尼松/泼尼松龙标准治疗方案，主要终点rPFS、 OS），招募736人，2031年1月取得结果。 202 （映恩生物） B7-H3 ADC 爆发前夜：III 期密集落地，千亿市场雏形初现 事件：2026年1月26日，clinicaltrials网址显示，BioNTech启动了BNT324（DB-1311）的首个III期临床试验（化疗未 经治的转移性去势抵抗性前列腺癌mCRPC，DB-1311vs多西他赛+泼尼松/泼尼松龙标准治疗方案，主要终点rPFS、 OS），招募736人，2031年1月取得结果。 2023年映恩生物DB-1311被授权至BioNTech，是第5款进入III期阶段的B7-H3 ADC，具全球商业 ...

Core Viewpoint - The global antibacterial drug market is steadily expanding, driven by demand and technology, with an expected market size of approximately $56 billion by 2025. In contrast, the Chinese market is experiencing a slight decline due to volume-based procurement policies, with projected market sizes of 122.9 billion yuan in 2024 and about 118.9 billion yuan in 2025 [1][4]. Antibacterial Drug Industry Overview - Antibacterial drugs are commonly used for the treatment and prevention of infections caused by bacteria, mycoplasma, chlamydia, rickettsia, spirochetes, and fungi. However, misuse and over-prescription have led to significant antibiotic resistance issues [2][3]. - The Chinese antibacterial drug market has been stable but is facing a slight downward trend due to volume-based procurement policies. The total market size for systemic antibacterial drugs in Chinese medical institutions is projected to be 109.18 billion yuan in 2024, a decrease of 18.29 billion yuan from 2023 [4][5]. Antibacterial Drug Market Structure - In 2024, the sales distribution of antibacterial drugs in China is as follows: urban hospitals account for 52.2%, county hospitals 21.8%, township health centers 19.0%, and community health centers 6.9% [4][5]. - The global antibacterial drug market is expected to reach $57.1 billion by 2026, indicating continued growth in the coming years [3]. Industry Chain - The upstream of the antibacterial drug industry includes raw materials such as penicillin industrial salt, cephalosporin intermediates, quinolones, and erythromycin thiocyanate. The midstream involves the production of antibacterial drugs, while the downstream applications are in medical terminals and agricultural/animal use [5]. Industry Development Environment - The antibacterial drug sector is crucial for treating infectious diseases, but the misuse of these drugs has led to increased bacterial resistance, diminishing their effectiveness. To combat this, the government has implemented a series of regulations and policies aimed at managing and monitoring the use of antibacterial drugs [5]. Competitive Landscape - Major players in the domestic antibacterial drug market include companies like Chuaning Biological, Dongyang Sunshine Pharmaceutical, and Hansoh Pharmaceutical, focusing on antibiotic intermediates and finished drug production [6]. - Danuo Pharmaceutical, established in 2013, is nearing commercialization with innovative drug products targeting bacterial infections and related diseases. The company reported a net loss of 38 million yuan in Q1 2025, primarily due to high R&D expenditures [7]. - Chuaning Biological has established a large-scale industrial production system for antibiotic intermediates, achieving a revenue of 2.349 billion yuan in the first half of 2025, with 92.88% coming from pharmaceutical manufacturing [8]. Research and Development Trends - The focus of future antibacterial drug research will be on addressing antibiotic resistance challenges, with increased investment in innovative technologies expected to enhance R&D efficiency [8].